Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

October 27, 2020 27 October, 2020

Sernova to Present at TSX Life Sciences Investor Day

Sernova Retains Integral Wealth Securities for Market Making Services

October 27, 2020 9:00 a.m. EDT

LONDON, ONTARIO – October 27, 2020 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company, announced today that Dr. Philip Toleikis, President and CEO, will provide an investor presentation at the upcoming TSX Life Sciences Investor Day being held on October 29, 2020, from 11:00 AM – 12:30 PM EST hosted by the Toronto Stock Exchange and the TSX Venture Exchange.

For more details on the event or to register to hear presentations from some of the most interesting public and private Life Sciences companies from Canada, please click HERE (https://produceredition.webcasts.com/starthere.jsp?ei=1384782&tp_key=2e4549bdfb).

Sernova also announces having retained the services of Integral Wealth Securities Limited to provide market- making services for the Company in compliance with the applicable policies of the TSX Venture Exchange. Integral will trade the securities of Sernova on the TSX Venture Exchange for the purpose of maintaining an orderly market and to provide liquidity of the Company's common shares.

Under the conditions of the agreement, Integral will be paid $7,000 per month for their services for a minimum term of 12 months. During the initial 12-month period, Sernova will have a one-time right to terminate after three months, provided written notice of termination is received at least 7 days prior to the 90th day of the term. After the 12th month of the term, this agreement may be terminated by the Company upon 30 days written notice.

There are no performance factors contained in the agreement, and Integral will not receive shares or options as compensation. Sernova and Integral are unrelated entities, and Integral has no present direct or indirect interest in the Company or its securities.

ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch™) and immune protected therapeutic cells/tissues (i.e. human donor cells, corrected human cells, and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT SERNOVA'S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device, upon implantation, is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins, hormones, or other factors as required to treat disease. Sernova is currently conducting a Phase I/II study at the University of Chicago and has demonstrated encouraging early safety and efficacy indicators. The Cell Pouch, in combination with therapeutic cells/tissues, has been shown to provide long-term safety and efficacy in preclinical models of diabetes, hemophilia A and other indications supporting our therapeutics platform.

For further information contact: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Forward-Looking Information This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the Company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the Company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the Company's Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the Company's quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.